{
    "clinical_study": {
        "@rank": "126347", 
        "brief_summary": {
            "textblock": "This study is being conducted to evaluate the effectiveness and safety of LAMICTAL added to\n      the current therapy of pediatric patients age 1-24 months old with partial seizures.  The\n      medication used in this study has been approved by FDA for the adjunctive treatment of\n      partial seizures in patients 2 years and older."
        }, 
        "brief_title": "Pediatric Epilepsy Trial in Subjects 1-24 Months", 
        "condition": "Epilepsy", 
        "condition_browse": {
            "mesh_term": "Epilepsy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA:\n\n          -  Have a confident diagnosis of epilepsy\n\n          -  Must be experiencing 4 or more reliably detectable partial seizures per month while\n             receiving at least 1 anti-epileptic drug (AED)\n\n          -  Must weigh at least 7 lbs if currently receiving enzyme inducing antiepileptic drugs\n             (EIADs)   OR  weigh at least 15 lbs if currently receiving non-enzyme inducing\n             antiepileptic drugs (non-EIADs)\n\n          -  Have no underlying chronic metabolism problems\n\n          -  Have normal lab results\n\n          -  Have a normal electrocardiogram (ECG)\n\n        EXCLUSION CRITERIA:\n\n          -  Have a diagnosis of severe, progressive myoclonus.\n\n          -  Have seizures not related to epilepsy.\n\n          -  Have previously demonstrated sensitivity or allergic reaction to the study drug or\n             its related compounds.\n\n          -  Have progressive or unstable condition of the nervous system.\n\n          -  Used experimental medication within 30 of enrollment into the study.\n\n          -  Have any significant, chronic heart, kidney, liver or stomach/intestinal (GI)\n             condition.\n\n          -  Current use of the medication felbamate.\n\n          -  Current use of adrenocorticotrophic hormone (ACTH).\n\n          -  Following a ketogenic diet.\n\n          -  Receiving vagal nerve stimulation (VNS)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "24 Months", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2002", 
        "id_info": {
            "nct_id": "NCT00043875", 
            "org_study_id": "LAM20006"
        }, 
        "intervention": {
            "intervention_name": "lamotrigine", 
            "intervention_type": "Drug", 
            "other_name": "lamotrigine"
        }, 
        "intervention_browse": {
            "mesh_term": "Lamotrigine"
        }, 
        "keyword": [
            "partial seizures", 
            "pediatric", 
            "epilepsy"
        ], 
        "lastchanged_date": "April 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85712"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72202"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90027"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305-5235"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80218"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20010"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32207"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33155-3009"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32835"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tallahassee", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32308"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33607-6350"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30342"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Augusta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30912"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40536-0284"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Paul", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55102-2383"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64108"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27607"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Akron", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44308-1062"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43205"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97227"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37212"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75230"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perth", 
                        "country": "Australia", 
                        "state": "Western Australia"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tartu", 
                        "country": "Estonia", 
                        "zip": "51014"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riga", 
                        "country": "Latvia", 
                        "zip": "LV 1004"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beirut", 
                        "country": "Lebanon", 
                        "zip": "11072020"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3015 GD"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Palmas De Gran Canaria", 
                        "country": "Spain", 
                        "zip": "35016"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Estonia", 
                "Latvia", 
                "Lebanon", 
                "Netherlands", 
                "Spain", 
                "Turkey"
            ]
        }, 
        "official_title": "A Double-Blind, Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics and Efficacy of Lamictal in Pediatric Age Subjects (1-24 Months)", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Lithuania: State Medicine Control Agency - Ministry of Health", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_outcome": {
            "measure": "The efficacy of LAMICTAL add-on therapy will be measured by the proportion of subjects who meet escape criteria during the Double-Blind Phase.", 
            "time_frame": "36 Months"
        }, 
        "removed_countries": {
            "country": [
                "France", 
                "Hungary", 
                "Italy", 
                "Lithuania", 
                "Portugal", 
                "Slovakia", 
                "Egypt"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00043875"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Time to escape patterns in Double-Blind phase. Reduction in partial seizure frequency at end of Open-Label Phase. Investigators' global evaluation of subjects' status at end of Open-Label and Double-Blind Phases; Standard pharmacokinetics; Adverse Events", 
            "time_frame": "36 Months"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2000", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2011"
    }, 
    "geocoordinates": {
        "GSK Investigational Site": "39.921 32.854"
    }
}